Results 81 to 90 of about 16,388 (147)

Therapeutic Potential of PCSK9 Inhibitors in Regulating Neuroinflammation in Acute Ischemic Stroke. [PDF]

CNS Drugs
Pu L, Liu J, Kong S, Joyama Y, Gong X, Ji X, Dong H.   +6 more
europepmc   +1 more source

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy. [PDF]

J Am Heart Assoc
Wu T, Zhao X, Xiao M, Deng J, Chen Z, Cheng D, Pan S, Liu X, Wu Y, Huang K.   +9 more
europepmc   +1 more source

Dose Up-Titration of a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Markedly Elevated Lipoprotein(a) in a Patient With Familial Hypercholesterolemia: A Case Report. [PDF]

Cureus
Suzuki N, Kishi H.
europepmc   +1 more source

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia

Chinese Medical Journal, 2022
Yanren Peng, Danxia Guo, Sijie Jiang, Hua Zheng, Lishao Guo   +4 more
doaj   +1 more source

Transforming growth factor beta reduces proprotein convertase subtilisin/kexin type 9 in the supernatant of hepatic stellate cells. [PDF]

World J Hepatol
Bundschuh J, Neumann M, Zimny S, Spirk M, Buechler C.   +4 more
europepmc   +1 more source

PCSK9 Inhibitor Use and the Risk of Age-Related Macular Degeneration in Patients with Atherosclerotic Cardiovascular Disease. [PDF]

Pharmaceuticals (Basel)
Tsai HR, Hsu JZ, Loh CH, Huang HK.
europepmc   +1 more source

Epithelial PCSK6 Promotes Proliferation and Decreases Collagen Deposition by Fibroblasts Potentially via MMP Activation. [PDF]

Int J Mol Sci
Tian Q, Dijkhuis A, Remmerswaal EBM, Aberson H, Crestani B, van der Poll T, Spek CA, Duitman JW.   +7 more
europepmc   +1 more source

Multi-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction. [PDF]

Int J Cardiol Heart Vasc
Horbach T, Wenzl FA, Manka R, Räber L, Carballo D, Keller T, Sossalla S, Ruschitzka F, von Eckardstein A, Stähli BE, Lüscher TF, Klingenberg R.   +11 more
europepmc   +1 more source

Effects of lipid-lowering drugs on epilepsy and its subtypes: A drug-target Mendelian randomization study. [PDF]

Medicine (Baltimore)
Wang Y, Huang S.
europepmc   +1 more source

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study. [PDF]

J Int Med Res
Wang Y, Liu X, Huang S.
europepmc   +1 more source